Koru Medical Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.
The agreement is intended for Koru to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized drug therapy. It also includes a close collaboration with Schott Pharma. Koru expects it to mark the first of multiple joint projects with Schott.
Under the agreement, Koru plans to develop a new, innovative system using its own infusion technology with Schott Toppac prefillable polymer syringes (PFS).
“This collaboration marks another milestone in our strategy to provide the most convenient infusion experience to SCIg patients,” said Linda Tharby, president and CEO of Koru Medical. “To receive the full benefit from innovative SCIg medications, including new formats like prefilled syringes, patients need an infusion system that is easy to use, fits into their lifestyles, and can efficiently deliver the drug they have been prescribed.
“This next-generation infusion system is intended to facilitate easier home therapy, whether the drug is dispensed via a vial or prefilled syringe. We are excited that this project includes a close collaboration between Koru and Schott Pharma.”
In 2023, the company inked a separate development agreement with a manufacturer of subcutaneous immunoglobulin therapy (SCIg). The deal sought to garner regulatory clearance for Freedom Infusion System with an SCIg prefilled syringe.
